Wow Debbie So U think there’s NO chance Kaiser’s MITIGATE trial will show any benefit in CV risk reduction They have 2 yr CV dats on the first 500 enrolled…. And 2 yr data on at least 1,000 by mid 2023 when they wind this up
For those 1,000 followed for 2 yrs …. If there’s no separation in event lines by then in this high risk US population on 4 gms of Vascepa …. well U will be right .
Doubt generic V or combo will amount to anything RESPECT EPA …. In my view … disappointing trial and hasn’t moved the needle ….. Kiwi
Baker Bros obviously have resources that most of us do not to analyze this stock situation . Offloading all of their shares cannot in any way be construed as a favorable action for the stock. Yes they could be wrong but more often than not they are right and that's why they are so wealthy.
AS I have said all along the only possible hope is the Healthnet case. If that is won and if Denner can remove the current nincompoops running the company there may be a chance to make some $.
I viewed winning the Healthnet case as a strong positive in the past but now even if won I have serious questions regarding AMRN's capability to capitalize on it.
I am now looking at it as more of a short play for a small blip in stock price - then once AMRN begins to manage the gift they were given price will probably drop as they apply their incompetence .
News 
Market Data 
Discover 
